Neuromyelitis Optica Spectrum Disorders
Conditions
Interventions
AZA group:N/A
MMF group:N/A
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age = 14 years; (2) The disease of Neuromyelitis Optica Spectrum Disorders with positive AQP4 IgG was confirmed; (3) Take mycophenolate mofetil or azathioprine as long-term immunotherapy;
Exclusion criteria
Exclusion criteria: (1) Neuropathy with progressive deterioration not related to the Neuromyelitis Optica Spectrum Disorders (2) There are Bone marrow suppression such as white blood cell count2 times normal upper value); HBsAg surface antigen positive patients are not allowed to be selected, but only patients with single positive anti HBc antibody will undergo HBV-DNA quantitative testing. If the HBV-DNA quantitative test is negative, it will not be considered excluded; (4) Pregnant women, breast-feeding women and patients with birth plans in the past 48 weeks; (5) Patients who have received any clinical trial drug within 28 days prior to enrollment or within 5 times the half-life of the trial drug (whichever is shorter); (6) Patients after splenectomy; (7) Patients with severe symptoms of mental disorders who cannot cooperate with the clinic; (8) Cyclosporine, tacrolimus, and aluminum during taking mycophenolate mofetil or azathioprine or magnesium antacid, and the drug has not been stopped for more than 3 months; (9) Vaccination during treatment. (10) Patients who are not suitable for the trial according to the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of first clinical relapse after enrollment; | — |
Secondary
| Measure | Time frame |
|---|---|
| frequency of recurrence; | — |
Countries
China
Contacts
Public ContactYangtai Guan
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Outcome results
None listed